Masthead

Accelerate your Oncology Research

Masthead

The aggressive pace of oncology research is characterized by large-scale, multidisciplinary efforts such as The Cancer Genome Atlas, The Human Protein Atlas, and Precision Medicine Initiative. With a broader and deeper understanding of the biology and signaling pathways that lead to cancer, scientists are better equipped to identify, characterize, and target biomarkers that can be translated into clinical applications. However, with these recent advancements comes a desperate need to understand the influence of the tumor microenvironment on cancer progression, evolution, and the resulting immune response. To make this next leap forward, scientists need tools that enable them to take an integrated, multi-omic, and 360° view of the tumor, immune response and microenvironment.

Challenges

Novel single-cell cancer genomics studies and spatial biology have led to new insights on tumor heterogeneity. NanoString’s GeoMx Digital Spatial Profiling (DSP) technology allows for a thorough exploration of the complex interactions with the tumor microenvironment through visualization and quantification of transcripts and proteins on individual tissue sections

Coupled with nCounter expression panels focused on clinical research, immuno-oncology, cancer metabolism, and CAR-T cell therapy, NanoString provides solutions for every step of the way in cancer research, from bulk gene expression analysis to spatial profiling.

NanoString offers solutions that overcome the biggest challenges in cancer research:

  • The complex interactions between the tumor and microenvironment
  • A highly heterogeneous disease that leads to variable therapeutic response
  • An ever-increasing number of possible therapeutic targets and combination trials

NanoString’s nCounter oncology gene expression panel portfolio has driven innovation since its inception, starting with the initial Hallmarks of Cancer Panel Collection and the best-selling PanCancer Immune Profiling Panel and PanCancer Pathways Panel. Expanding on this, the 360 Series Panel Collection and Data Analysis Service allow researchers to better understand therapeutic response/mechanism of action, immune evasion, and the interplay between the tumor and microenvironment.

Case Studies

Biomarkers for adjuvant
therapy predict benefit in early stage triple negative breast cancer

Read More
3d model of a cell

PanCancer IO 360
& GeoMx DSP Case Study – Pediatric Primary and Metastatic Osteosarcoma

Read More
Case Study

Related Resources

View All Resources
Blog From an Egyptian Papyrus to the Hallmarks of Cancer: A Journey through the Development of Knowledge in Oncology Research
Blog Going Beyond PDL-1. Q&A with Dr. Nina Radosevic- Robin, MD.
Blog Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Blog Experts Discuss Digital Spatial Profiling in Immuno-Oncology
Tradeshow/Conference Advancing Science: A Virtual Oncology Conference

Publications

View All Publications

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.

Cancer immunotherapies have generated remarkable clinical responses for some patients with advanced/metastatic disease, prompting exploration of rational combination therapies to bolster anti-tumor immunity in patients with limited response or those who experience tumor progression following an initial response to immunotherapy. In contrast to other tumor indications, objective response rates to single-agent PD-1/PD-L1 blockade in ovarian cancer are limited, suggesting a need to identify combinatorial approaches that lead to tumor regression in a setting where checkpoint blockade alone is ineffective.

Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer.

BACKGROUND: Currently, over half of breast cancer cases are unrelated to known risk factors, highlighting the importance of discovering other cancer-promoting factors. Since crosstalk between gut microbes and host immunity contributes to many diseases, we hypothesized that similar interactions could occur between the recently described breast microbiome and local immune responses to influence breast cancer pathogenesis.

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.

Background: high recurrence rates of up to 75% within 2 years in pancreatic ductal adenocarcinoma (PDAC) patients resected for cure indicate a high medical need for clinical prediction tools and patient specific treatment approaches. Addition of the EGFR inhibitor erlotinib to adjuvant chemotherapy failed to improve outcome but its efficacy in some patients warrants predictors of responsiveness.